HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nitro, Polycyclic Musk Risk Assessment Should Not Be Altered – FMA

This article was originally published in The Rose Sheet

Executive Summary

The results of a study published in the National Institute of Environmental Health Sciences' Environmental Health Perspectives evaluating the impact of nitromusks and polycyclic musks on excised gill tissues in mussels should not impact the safe use of the common fragrance ingredients or alter environmental risk assessments for the chemicals, the Fragrance Materials Association said in a Nov. 5 statement

You may also be interested in...



Fragrance Industry Claims WWF Chemicals Report Is Misleading

In a recent report surveying chemicals found in the blood of 14 European Ministers, the World Wildlife Fund distorts the threat of several fragrance chemicals, according to industry. The Fragrance Materials Association responded to the study Nov. 12, stating the report "unjustifiably groups these materials with chemicals that have known health risks, such as DDTs and PCBs, while not making an adequate scientific case for risks from materials used in fragrances.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel